Monebias v. Boehringer Ingelheim Pharmaceuticals, Inc.

Filing 6

CONDITIONAL TRANSFER ORDER (CTO-1). CASE TRANSFERRED to Southern District of Illinois. MDL No. 2385. (Robles, S) [Transferred from California Eastern on 8/16/2012.]

UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION

IN RE: PRADAXA (DABIGATRAN ETEXILATE)
PRODUCTS LIABILITY LITIGATION

FILED
(SEE ATTACHED SCHEDULE)

MDL No. 2385

AUG 15 2012

CLERK, U.S. DISTRICT COURT
SOUTHERN DISTRICT OF ILLINOIS
EAST ST. LOUIS OFFICE

CONDITIONAL TRANSFER ORDER (CTO -1)

On August 8, 2012, the Panel transferred 13 civil action(s) to the United States District Court for the
Southern District of Illinois for coordinated or consolidated pretrial proceedings pursuant to 28
U.S. C.§ 1407. See _F.Supp.2d_ (J.P.M.L. 2012). Since that time, no additional action(s) have been
transferred to the Southern District of Illinois. With the consent of that court, all such actions have
been assigned to the Honorable David R Herndon.
It appears that the action(s) on this conditional transfer order involve questions of fact that are
common to the actions previously transferred to the Southern District of Illinois and assigned to
Judge Herndon.
Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict
Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the
Southern District of Illinois for the reasons stated in the order of August 8, 2012, and, with the
consent of that court, assigned to the Honorable David R Herndon.
This order does not become effective until it is filed in the Office of the Clerk of the United States
District Court for the Southern District of Illinois. The transmittal of this order to said Clerk shall be
stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the
Panel within this 7-day period, the stay will be continued until further order of the Panel.

FOR THE PANEL:

~
Jeffery N. LUthi
Clerk of the Panel

IN RE: PRADAXA (DABIGATRAN ETEXILATE)
PRODUCTS LIABILITY LITIGATION

MDL No. 2385

SCHEDULE CT0-1- TAG-ALONG ACTIONS

C.A.NO.

CASE CAPTION

CALIFORNIA EASTERN
CAE

1

12-01106

Monebias v. Boehringer Ingelheim Pharmaceuticals,
Inc. l'l:bOOOI DrtH ~CW

CALIFORNIA NORTHERN
CAN

3

12-03715

Butner et al v. Boehringer Ingelheim Pharmaceuticals,
Inc. et al 12·60002 Df<H SCW

GEORGIA SOUTHERN
GAS

4

12-00187

Ellis et al v. Boehringer Ingelheim Pharmaceuticals,
Inc. et alt1· b0003 P~H

sew

KENTUCKY WESTERN
KYW

5

12-00099

Evans v. Boehringer Ingelheim Pharmaceuticals, Inc.
et al \I·b0004 l>Y{H )Cw

LOUISIANA EASTERN
LAE

2

12-01389

LAE

2

12-01544

Jackson v. Boehringer Ingelheim Pharmaceuticals, Inc.
etal \?:bOO()co D\f(H ~C.W
Sykes v. Boehringer Ingelheim Pharmaceuticals, Inc.
et al \'2:.boOOb D~\\ StW

NEW JERSEY
NJ

2

12-03808

ARMIGER v. BOEHRINGER INGELHEIM
PHARMACEUTICALS, INC. et all2·~()0Ql

NEW YORK EASTERN
NYE

1

12-02936

NEW YORK SOUTHERN

Ecklund et al v. Boehringer Ingelheim
Pharmaceuticals, Inc. et al l?..-\:.000~ {)~\-\ )CW

0£.\tSC.W

_,

NYS

12-05458

Swing v. Boehrin~~r Ingelheim Pharmaceuticals, Inc.
et al 11·6booq P "H SC-W

12-01382

1

Maxene A. Gennaro et al v. Boehringer In_gelheim
Pharmaceuticals, Inc. et al \1 ·bOOt() 0 '(\t <;C-W
Bullock v. Boehringer Ingelheim Pharmacueticals,Inc.
et al \1 ·loObll D~ t\ c;cw

OHIO NORTHERN

OHN
OHN

5

12-01753

OHIO SOUTHERN
OHS

1

12-00511

Derrick v. Boehringer Ighelheim Pharmaceutical Inc.
et al \2lo6012 bR.\\ sew

Sessoms et al v. Boehringer Ingelheim
.. 1
Pharmaceuticals Inc et al \1.:600\ ~ P~ \-\ ~C V\1
Martin v. Boehringer Ingelheim Pharmaceuticals Inc et
al \?.:loCO\~ ~'(\\ ~t

SOUTH CAROLINA

sc

2

12-01698

sc

2

12-01921

w

TENNESSEE MIDDLE
TNM

3

12-00605

Giles v. Boehringer Ingelheim Pharmaceuticals, Inc. et
alt2·bbO\S O~H seW